Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease.

Abstract

AIMS:

Obesity is associated with progression of chronic kidney disease (CKD). Treatment with bardoxolone methyl in a multinational phase 3 trial, Bardoxolone Methyl Evaluation in Patients with Chronic Kidney Disease and Type 2 Diabetes (BEACON), resulted in increases in estimated glomerular filtration rate (eGFR) with concurrent reductions in body weight. We performed post-hoc analyses to further characterize reductions in body weight with bardoxolone methyl.

METHODS:

Eligible patients with type 2 diabetes (T2DM) and CKD stage 4 (eGFR 15 to <30 mL/min/1.73 m2) were randomized 1:1 to receive once-daily oral dose of bardoxolone methyl (20 mg) or placebo.

RESULTS:

BEACON enrolled 2185 patients. Patients randomized to bardoxolone methyl experienced significant reductions in body weight from baseline relative to patients randomized to placebo (-5.7 kg; 95% CI: -6.0 to -5.3 kg; p < 0.001). In patients randomized to bardoxolone methyl, rate and magnitude of body weight loss were proportional to baseline BMI. Bardoxolone methyl resulted in significant reductions in waist circumference and improved glycemic control.

CONCLUSIONS:

Bardoxolone methyl resulted in significant weight loss in a generally obese patient population with T2DM and stage 4 CKD, with the magnitude and rate dependent on baseline BMI.

• Authors: Glenn M Chertow, Gerald B Appel, Geoffrey A Block, Melanie P Chin, Daniel W Coyne, Angie Goldsberry, Kamyar Kalantar-Zadeh, Colin J Meyer, Mark E Molitch, Pablo E Pergola, Philip Raskin, Arnold L Silva, Bruce Spinowitz, Stuart M Sprague, Peter Rossing
• Journal: Journal of diabetes and its complications (J Diabetes Complications) Vol. 32 Issue 12 Pg. 1113-1117 (Dec 2018) ISSN: 1873-460X [Electronic] United States
• PMID: 30318163 (Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
• Copyright: Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Chemical References

• Blood Glucose
• Glycated Hemoglobin A
• hemoglobin A1c protein, human
• Oleanolic Acid
• bardoxolone methyl

Topics

• Aged
• Blood Glucose (drug effects, metabolism)
• Body Weight (drug effects)
• Diabetes Mellitus, Type 2 (blood, complications, drug therapy)
• Diabetic Nephropathies (blood, drug therapy, pathology)
• Disease Progression
• Double-Blind Method
• Female
• Glomerular Filtration Rate (drug effects)
• Glycated Hemoglobin (drug effects, metabolism)
• Humans
• Male
• Middle Aged
• Obesity (blood, complications, drug therapy)
• Oleanolic Acid (analogs & derivatives, pharmacology, therapeutic use)
• Renal Insufficiency, Chronic (blood, drug therapy, pathology)
• Waist Circumference (drug effects)